Study of TAK-672 in Participants With Acquired Hemophilia A

  • End date
    Nov 30, 2022
  • participants needed
  • sponsor
Updated on 23 March 2022


The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672. Acquired hemophilia A is when people's immune system attacks specific proteins, known as clotting factors, in their bodies. This is different from hemophilia A, which is a condition people are born with.

At the first visit, the study doctor will check who can take part. For those who can take part, participants will visit the clinic or hospital when they get their next bleed. They will receive TAK-672 slowly through a vein. This is called an infusion. They might need extra infusions of TAK-672 to control the bleed. After their bleed is controlled, participants will regularly visit the clinic for a check-up and to treat any further bleeds. This will happen until all participants have received their last dose of TAK-672 to control their 1st bleed. After this, all participants will visit the clinic 90 days later for a final check-up.


Efficacy and Safety Evaluation of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in Japanese Participants with AHA

Condition Acquired Hemophilia A
Treatment TAK-672
Clinical Study IdentifierNCT04580407
Last Modified on23 March 2022


Yes No Not Sure

Inclusion Criteria

Male or female Japanese participants of >=18 years of age
Participants who (or their legally authorized representatives) have provided his/her written informed consent form prior to any study-related procedures and study product administration
Participants with a diagnosis of AHA based on clinical evaluation and supportive local laboratory testing as shown below
Presentation with spontaneous bleeding without anatomical cause and without prior known bleeding disorder
Prolonged activated partial thromboplastin time (aPTT) without explanation
Abnormal aPTT cross mixing test consistent with FVIII inhibitors
Confirmation of a low FVIII:C
Positive FVIII inhibitor (>=0.6 BU) as measured either in the local or central laboratory
Participants with a severe bleeding episode which the investigator finds necessary to
treat and whose severe bleeding episode meets at least 1 of the following
Bleeds that pose a threat to a vital organ that could threaten life (e.g. intracranial bleed, or any site that could obstruct the airway)
Bleeds that pose a threat to a vital organ where life is not threatened but the organ function could be impaired (e.g., intraspinal bleed threatening the spinal cord and/or nerve conduction; a continual bleed into the kidney or bladder that could result in an obstructive uropathy, testicular bleed, bleed in and around the eye)
Bleeds requiring a blood transfusion to maintain the Hgb level at above-life or organ threatening levels (e.g. post-surgical, gastro-intestinal, retro-peritoneal, and thigh bleeds)
Intramuscular bleeds where muscle viability and/or neurovascular integrity is significantly compromised or at risk of being compromised
Intra-articular bleeds impacting a major joint associated with severe pain, swelling and severe loss of joint mobility (reduced >70%) or where a bleed could result in joint destruction (e.g. in and around the femoral head)
Participants who are taking anti-thrombotics (including anti-platelet agents and
anticoagulantswith confirmatory laboratory testing documenting specific FVIII
inhibitor titer and with 3 half-lives of the agent have elapsed since the last
Participants with expected life expectancies of at least 90 days prior to the onset of the hemorrhagic episode
Participants of reproductive age who have agreed to use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process
Participant who are able to willing and able to comply with the requirements of the protocol

Exclusion Criteria

Participants with an established reason for bleeding that is not correctable even with hemostatic therapy
Participants presenting a bleeding episode that is assessed likely to resolve on its own, even if left untreated
Participants with a known major sensitivity (anaphylactoid reactions) to therapeutic products of porcine or hamster origin; examples include therapeutics of porcine origin (e.g. previously marketed porcine FVIII, Hyate: C) and recombinant therapeutics prepared from hamster cells (e.g. Humira, Advate, and Enbrel)
Participants with the use of hemophilia medication: prior to the administration of TAK-672 under one of the following conditions: (1) use of "recombinant activated factor VII (rFVI)Ia " within 3 hours prior to TAK-672 administration (2) use of " activated prothrombin complex concentrate (aPCC)" within 6 hours prior to TAK-672 administration or (3) use of " plasma-derived FX/FVIIa complex concentrate (pd-FX/FVIIa) " within 8 hours prior to TAK-672 administration
Participants with an anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of TAK-672, or whose safety or efficacy may be affected by TAK-672
Participants who are currently pregnant or breastfeeding, or planning to become pregnant or father a child during the study
Participants who have participated in another clinical study and has been exposed to an investigational product or device within 30 days prior to the study enrollment
Participants who are scheduled to participate in another non-observational (interventional) clinical study involving an investigational product or device during the course of the study
Participants who are unable to or unwilling to comply with the study design, protocol requirements, and/or the follow-up procedures
Participants whose majority of age are under legal protection
Participants who are an immediate family member, study site employee, or are in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g. spouse, parent, child, sibling) or may consent under duress
Participants who are judged by the investigator as being ineligible for any other reason
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note